New Mouse Models for Lung Cancer with EGFR T790M Mutations
Author Information
Author(s): Regales Lucia, Balak Marissa N., Gong Yixuan, Politi Katerina, Sawai Ayana, Le Carl, Koutcher Jason A., Solit David B., Rosen Neal, Zakowski Maureen F., Pao William
Primary Institution: Memorial Sloan-Kettering Cancer Center
Hypothesis
The EGFRT790M mutation plays a significant role in lung tumorigenesis and resistance to kinase inhibitors.
Conclusion
The developed mouse models provide insights into the role of EGFRT790M in lung cancer and may aid in developing better therapies.
Supporting Evidence
- EGFRT790M mutations are linked to resistance against EGFR inhibitors in lung cancer.
- Mouse models developed show that EGFRT790M alone can induce lung tumors.
- Treatment with erlotinib did not yield significant responses in tumors driven by EGFRT790M.
- 17-AAG treatment showed some antitumor effects but was not sustained.
Takeaway
Scientists created special mice that have a mutation making them resistant to certain cancer treatments, helping us understand how to fight lung cancer better.
Methodology
Mice with inducible expression of EGFRT790M were developed to study lung tumorigenesis and treatment responses.
Limitations
The study primarily focuses on mouse models, which may not fully replicate human lung cancer complexities.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website